Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia.

Tytuł:
Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia.
Autorzy:
Arends TJ; Department of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. .
Falke J; Department of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. .
Lammers RJ; Department of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. Rianne_.
Somford DM; Canisius Wilhelmina Ziekenhuis, Weg door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands. .
Hendriks JC; Biostatistician, Department for Health Evidence, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. .
de Weijert MC; Department of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. .
Arentsen HC; Department of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. .
van der Heijden AG; Department of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. .
Oosterwijk E; Department of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. .
Alfred Witjes J; Department of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. .
Źródło:
World journal of urology [World J Urol] 2015 Oct; Vol. 33 (10), pp. 1411-7. Date of Electronic Publication: 2014 Dec 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [Berlin ; New York] : Springer International, 1983-
MeSH Terms:
Carcinoma, Transitional Cell/*therapy
Cytokines/*urine
Hyperthermia, Induced/*methods
Mitomycin/*administration & dosage
Urinary Bladder Neoplasms/*therapy
Administration, Intravesical ; Aged ; Aged, 80 and over ; Antibiotics, Antineoplastic/administration & dosage ; Biomarkers, Tumor/urine ; Carcinoma, Transitional Cell/pathology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Instillation, Drug ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Urinary Bladder Neoplasms/pathology
References:
J Urol. 2009 Nov;182(5):2195-203. (PMID: 19758621)
Biomed Res Int. 2013;2013:791212. (PMID: 23762858)
Cancer Immunol Immunother. 2002 Apr;51(2):91-8. (PMID: 11904733)
Br J Clin Pharmacol. 2001 Sep;52(3):273-8. (PMID: 11560559)
World J Urol. 2009 Jun;27(3):289-93. (PMID: 19219610)
Eur Urol. 2003 Jun;43(6):637-45. (PMID: 12767365)
Int J Hyperthermia. 1988 Mar-Apr;4(2):143-58. (PMID: 3283266)
J Urol. 1996 Feb;155(2):477-82. (PMID: 8558640)
Eur Urol. 2004 Jul;46(1):65-71; discussion 71-2. (PMID: 15183549)
Eur Urol. 2013 Oct;64(4):639-53. (PMID: 23827737)
Eur Urol. 2012 Jan;61(1):128-45. (PMID: 22000498)
Am J Clin Pathol. 1996 May;105(5):589-98. (PMID: 8623768)
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3652-6. (PMID: 8170963)
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. (PMID: 16442208)
Cancer Chemother Pharmacol. 2010 Oct;66(5):981-6. (PMID: 20499068)
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. (PMID: 22237781)
Urology. 2004 Mar;63(3):466-71. (PMID: 15028439)
Annu Rev Biochem. 1990;59:783-836. (PMID: 1695833)
J Urol. 1999 Jan;161(1):67-71. (PMID: 10037371)
J Leukoc Biol. 1996 Sep;60(3):365-71. (PMID: 8830793)
J Clin Oncol. 2003 Dec 1;21(23):4270-6. (PMID: 14581436)
J Urol. 2009 Oct;182(4):1313-7. (PMID: 19683278)
Int J Urol. 2007 Feb;14(2):140-6. (PMID: 17302571)
World J Urol. 2009 Jun;27(3):295-300. (PMID: 19271220)
J Cancer Res Clin Oncol. 2011 Dec;137(12):1729-38. (PMID: 21932129)
Contributed Indexing:
Keywords: Bladder cancer; Bladder instillation; Chemotherapy; Cytokines; Induced hyperthermia
Substance Nomenclature:
0 (Antibiotics, Antineoplastic)
0 (Biomarkers, Tumor)
0 (Cytokines)
50SG953SK6 (Mitomycin)
Entry Date(s):
Date Created: 20141211 Date Completed: 20160719 Latest Revision: 20181113
Update Code:
20240104
DOI:
10.1007/s00345-014-1458-3
PMID:
25491674
Czasopismo naukowe
Objectives: To explore whether urinary cytokine and chemokine (CK) levels differed between cold mitomycin-C (cold-MMC)-treated patients and chemohyperthermia (C-HT)-treated patients, to shed light on the possible molecular mechanisms that might explain the superior outcome of C-HT. Furthermore, CK-differences were explored between C-HT responders and C-HT non-responders.
Methods: Twelve NMIBC patients were included. Nine received six-weekly C-HT, and three received four-weekly cold-MMC instillations. Urine was collected on 8-12 time points before and after every treatment. MDC, IL-2, IL-6, IL-8, IP-10, MCP-1 and RANTES were determined by Luminex(®)-analysis.
Results: Elevated urinary CK levels were observed in both groups after treatment. In general, CK-peaks were lower in the cold-MMC group in comparison with levels in the C-HT group. Significant higher MCP-1 and IL-6 levels were observed in C-HT-treated patients. Additionally, significant cumulative effects were observed for IP-10 and IL-2. However, IP-10 and IL-2 levels did not significantly differ between treatments. MDC levels after the first week of treatment were significantly higher in the C-HT responders compared with the non-responders.
Conclusion: MMC treatment leads to elevated urinary CK levels with significantly higher MCP-1 and IL-6 levels in C-HT-treated patients. Increased MDC levels after the first C-HT instillation appear to be related to good clinical outcome and might be of additional value to personalize treatment. Studies involving more patients and longer follow-up are needed to substantiate this observation.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies